Phase 1 part: Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with TG4050 in Head and Neck Cancer
TG4050
The lead Individualized Neoantigen Therapeutic Vaccine (INTV) from our myvac® platform, TG4050 is being further evaluated in a randomized multicenter Phase 2 part of a Phase 1/2 trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (HNSCC).
Discover TG4050
Phase 1 part: Proof of Principle in Patients in the Adjuvant Treatment of Head and Neck Cancers
Key news
about Phase 1 part
Download the Rapid Oral Presentation from ASCO 2025
Watch our Chief Medical Officer explain the key data from the trial
Listen to Pr. Ottensmeier explain his views on the data
In the Phase 1 part (n=32), all patients who received TG4050 remained disease-free for at least two years, providing strong clinical proof of principle.
These positive data presented at ASCO 2025 confirm that TG4050 treatment is safe and feasible in the adjuvant setting of resectable HPV-negative locally advanced head and neck squamous cell carcinoma (HNSCC).
When given as monotherapy in this trial, TG4050 met all trial endpoints and induced long lasting immune responses to vaccine neoantigens that were sustained for up to two years.
Phase 1/2 Critical Milestones
Phase 1 − Successfully completed
- Primary objectives achieved: safety and tolerability
- Secondary objectives achieved: feasibility, disease-free survival (DFS) => 100% 24-month DFS in treatment arm
- Additional immunological data from Phase I patients presented at SITC 2025
- Exploratory objectives: immunogenicity, exploratory tumor biomarkers (TMB, PD-L1) => confirm specific, effective and long-lasting immune response
Phase 2 − Ongoing
- Primary objective: 2-year median follow-up (2-year DFS)
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050 in the randomized multicenter Phase 1/2 trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers. This Individualized Neoantigen Therapeutic Vaccine is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
Additional ressources
Key presentation
Latest press releases

- April 13, 2026Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
- April 2, 2026Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
- January 9, 2026Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
- November 6, 2025Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
- October 3, 2025Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
- September 16, 2025Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
- June 19, 2025Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
- June 3, 2025Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
- June 1, 2025Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050
- June 1, 2025Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025